Authors


Emily Hirsch

Latest:

Are We Overdiagnosing and Overtreating ADHD?

This article speaks to the care with which ADHD must be diagnosed and managed to reduce the significant negative impact of the disorder on the individual, family, and society.


Emily O'Day

Latest:

Bereavement, Grief, and Depression: Clinical Update and Implications

An in-depth CME on DSM-5 criteria for persistent complex bereavement disorder and the clinical management of pathological reactions to the death of a loved one.


Emma Barkus, PhD

Latest:

The Link Between Psychotic Disorders and Substance Use

Psychotic disorders are a group of syndromes characterized by positive symptoms, including hallucinations, delusions, and thought disorder; and negative symptoms, including mood symptoms, social withdrawal, and reduced motivation. Cognitive deficits also appear with psychotic disorders. Psychotic disorders rank 22nd in the World Health Organization's list of worldwide causes of disability. This ranking is adjusted for the relatively low lifetime prevalence rate for psychosis; the perceived burden of the disease on those affected with psychotic disorders, as well as their relatives and caregivers, is much higher.


Emma Robertson-Blackmore, PhD

Latest:

Differential Diagnosis of Postpartum Psychosis

New mothers may present to the emergency department (ED) with symptoms ranging from mild anxiety to severe psychosis. Postpartum psychosis has abrupt onset and severe symptoms and usually occurs in the immediate postpartum period. Patients who have had a previous episode of postpartum psychosis or have first-degree relatives with postpartum psychosis or bipolar disorder are at higher risk.


Enrico Suardi, MD

Latest:

Symposium on Psychology and National Security at the Italian Embassy

The Embassy of Italy in Washington, DC recently hosted the first of 2 workshops on “Leaders and Terrorists: Psychological Perspectives on National Security.”


Eran Chemerinski, MD

Latest:

Monoaminergic Treatment of Schizophrenia

Although several clinical studies suggest that cognitive impairments in schizophrenia are associated with reduced stimulation of dopamine receptors in the prefrontal cortex, mounting evidence suggests that other monoaminergic neurotransmitter systems may also be involved. We provide an overview of neurotransmitters that hold promise as therapeutic interventions for the cognitive deficit in schizophrenia.


Eric Bui, MD, PhD

Latest:

Bereavement, Grief, and Depression: Clinical Update and Implications

An in-depth CME on DSM-5 criteria for persistent complex bereavement disorder and the clinical management of pathological reactions to the death of a loved one.


Eric C. Arauz, MLER

Latest:

Bipolar Disorder: Keys to Improving Compliance

Non-adherence to prescribed medication by patients with psychiatric disorders is one of the greatest challenges reported by clinicians.


Eric D. Caine, MD

Latest:

Special Report Chair Discusses Suicide

In this podcast, Dr Caine discusses the many issues associated with suicide and touches on specific articles in this Special Report.


Eric D. Peselow, MD

Latest:

SSRIs

Many of the advantages of the MAOIs are seen with selective serotonin reuptake inhibitors, which have become the drugs of choice in the treatment of panic disorder.


Eric Finzi, MD, PhD

Latest:

Botulinum Toxin for Depression? Emotional Proprioception

If larger trials confirm the strong antidepressant effects observed so far, botulinum toxin may become a standard therapeutic addition to the psychiatric armamentarium.


Eric Hollander, MD

Latest:

Understanding the Differences Between Impulsivity and Compulsivity

A review of targeted treatment strategies for symptom domains when impulsivity and compulsivity become dysfunctional.


Eric J. Lenze, MD

Latest:

Anthropology-Informed Business Principles for Brain Health

The key to addressing mental health may lie in business innovation theories.


Eric J. Nestler, MD, PhD

Latest:

New Insight Into the Neurobiology of Depression

Certain aspects of depression result from maladaptive stress-induced changes in reward circuits of the brain.


Eric L. Scott, PhD

Latest:

Anxiety Disorders With Comorbid Substance Abuse

Anxiety disorders occur in 18% to 28% of the US general population during any 12-month period. In anxiety disorder, there is a 33% to 45% 12-month prevalence rate for a comorbid substance use disorder (SUD).


Eric London, MD

Latest:

A Psychiatrist's Journey from Parent to Founder of Research Advocacy Organization

In 1988 I was working as a general adult psychiatrist with a specialty in addictions. One day, a newly referred patient came to my office accompanied by his mother. Although he was well groomed, he was distinctly "nerdy." When I inquired about his chief complaint, his mother quickly explained that, although he had graduated from community college, he was unable to secure a job interview due to his obsessing on the details of his resume.


Eric M Plakun, MD

Latest:

Treatment-Resistant Mood Disorders: A Psychodynamic Approach

In this podcast, Dr Eric Plakun give an overview of key points and psychodynamic principles on treatment-resistent mood disorders, based on research and clinical experience.


Eric M. Plakun, MD

Latest:

My First Lesson in Countertransference

Here's the story of one of my very first patients -- 45 years ago -- who taught me a powerful lesson about countertransference.


Eric T. Wong, MD

Latest:

Treatment Advances for Glioblastoma: Tumor Markers and Targeted Treatments

Although malignant brain tumors affect thousands of persons each year, treatment has not significantly advanced. For 3 decades, the standard of care was palliative surgery, radiation, and chemotherapy. Of these, radiotherapy was the only proven way to lengthen survival time. However, since 2005 the standard of treatment has changed thanks to studies showing posi- tive results from daily temozolo- mide (Temodar) combined with radiotherapy.


Erick H. Cheung, MD

Latest:

Oxford Handbook of Psychiatric Ethics

As our understanding of the brain and new technologies have rapidly evolved, such an extensive text on psychiatric ethics is clearly timely.


Ericka L. Adler

Latest:

E-mailing With Patients: Think Before You ‘Send’

When it comes to e-mail, I typically warn my [physician] clients of the following.


Erik R. Vanderlip, MD, MPH

Latest:

Depression and Diabetes: Improving Outcomes Through Collaborative Care

Depression and diabetes can prey on the shortcomings of our health care system, such as fragmented, episodic care and poor continuity. Coordinating care can be fraught with difficulties, but it is the goal of many current efforts in health care reform.


Erika L. Clark, MA

Latest:

Can Your Older Patient Drive Safely?

Medical professionals may be reluctant to initiate a discussion about driving with older patients in anticipation of a negative impact on the physician-patient relationship.


Erika Paradiso, MD

Latest:

Mood Stabilizers and Novel Antipsychotics in the Treatment of Borderline Personality Disorder

This article focuses on data concerning the efficacy of mood stabilizers in the treatment of BPD.


Erin B. Cooper, PhD

Latest:

Does Flibanserin Have a Future?

Before flibanserin, there were no FDA-approved treatments for hypoactive sexual desire disorder. The authors clarify the intricacies of an HSDD diagnosis and discuss implications for treatment.


Erin Carlton, MS

Latest:

Inflammation, Psychosis, and the Brain

When the solution to a clinical or scientific puzzle eludes us for more than a century, as with schizophrenia, we need new methods to examine the pathology. If we want to make an impact on the disease we must shift research paradigms and focus on the early detection, early intervention, and new avenues of treatment that address different symptoms of schizophrenia.


Erin E. Hayes, MSIV

Latest:

Synthetic Cathinones: Signs, Symptoms, and Treatment

Sometimes viewed as “legal cocaine,” the over-the-counter status of synthetic cathinones (aka bath salts) gives the illusion that they are safe. In fact, they are highly toxic.


Erin E. Michalak, PhD

Latest:

Quality of Life in Patients With Bipolar Disorder: Defining and Measuring Goals

A complex and heterogeneous condition characterized by a variety of symptoms and marked variability in disease course, bipolar disorder is marked by episodes of depression, hypomania, mania, or psychosis and,patients can experience a mixture of emotional states.


Erin K. Kastenschmidt, MD

Latest:

Evolution of Mental Health Disorders: An Alternative Perspective

In Angst: Origins of Anxiety and Depression, Dr Jeffrey Kahn offers an alternative perspective on the evolution of common mental health disorders by considering the adaptive nature of symptoms that modern clinicians deem pathological.


Erin L. Belfort, MD

Latest:

The Double-Edged Sword of Social Media: Exploring the Complex Relationships Between Social Media Use and Youth Mental Health

Youth today have a relatively nuanced and mixed experience with social media. How can you best navigate this relationship as a mental health clinician?

© 2025 MJH Life Sciences

All rights reserved.